Emerging trends and challenges in AAV manufacturing for gene therapies

Adeno-associated viral (AAV) vectors are the most prominent delivery vehicles being investigated for the treatment of genetic diseases. Although the successes of AAV-based gene therapies in pre-clinical and clinical studies are encouraging, limitations in vector characterization and manufacturing still pose significant challenges.

Here, a panel of experts in vector development and characterization will discuss the emerging trends and future challenges of AAV-based gene therapies. The panel will then dive deeper into analytical methods used to characterize vector critical quality attributes (CQAs) and highlight crucial areas for improvement in AAV manufacturing.

You will learn about:

• Key considerations in AAV vector development
• Important CQAs to characterize during vector engineering and manufacturing
• Insights into developing and optimizing robust analytical workflows

Matthew Fuller

Executive Director, Ultragenyx Gene Therapy - Research

Alix Eastham

Senior Manager, Cell Line Development, Ultragenyx Gene Therapy - Research

Ioannis (John) Eugenis

Product Manager, Bio-Techne